secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2022-03-14T23:59:59+00:00
Accession:  0000950170-22-003573
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences reports Q4/FY2021 net loss of $9.2M/$42.3M; cash $121.4M
---------------------------------------------------------------------------

- Cash, cash equivalents and investments of $121.4M as of Dec 31, 2021; expected to fund operations into Q2 2024.
- R&D expenses for FY2021: $30.7M, up from $23.9M in 2020; net loss widened to $42.3M from $29.5M.
- Appointed Will Charlton, M.D., M.A.S., as Chief Medical Officer in March 2022; he previously served at 89bio.
- Topline safety data from Cohort 1 of Phase 2 pediatric classic CAH study expected by 1H 2023; PCOS Phase 2 topline also by 1H 2023.
- CAHmelia-203 (adult classic CAH, poor disease control) topline by 2H 2023; CAHmelia-204 (good disease control) by 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017022003573/0000950170-22-003573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017022003573/sprb-20220314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer